ITUS Corporation ITUS
Set alert
At close · Jun 28
Day range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 86.75M
- Vol
- 0
- Avg vol
- 163.55K
- EPS
- -0.621
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 10.90
- Inst. own
- 4.77%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.64
- 200-d avg
- 3.64
- 1y target
- 1.12
Key statistics
- Market cap
- 86.75M
- Enterprise value
- 84.43M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 77.98
- Price / book
- 13.73
- EPS (TTM)
- -0.621
- Beta
- 1.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.11M
- Revenue growth
- 0.00%
- Free cash flow
- -175.08K
- Total cash
- 5.34M
- Total debt
- 0
- Return on equity
- -182.59%
- Shares outstanding
- 18.70M
- Short % of float
- 10.61%
- 50-day average
- 4.64
- 200-day average
- 3.64
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About ITUS Corporation
ITUS Corporation develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It also develops immuno-therapy drugs for the treatment of cancer. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. ITUS Corporation was founded in 1982 and is based in San Jose, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- ITUScorp.com
News
Your note
Sign in to keep a note on ITUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HERMS HENRY P | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 19, 2016 | 23,321 |
| JOHNSON BRUCE F | Director | Stock Award(Grant) | Sep 21, 2017 | 604,817 |
| MONAHAN JOHN J | Director | Stock Award(Grant) | Sep 21, 2017 | 50,000 |
| TITTERTON LEWIS H JR | Director | Conversion of Exercise of derivative security | Oct 18, 2017 | 834,544 |
| WILLIAMS RICHARD H | Director | Sale | Apr 8, 2018 | 25,000 |